Collectively, these results demonstrate that miR‐646 acts as a tumor suppressor in NSCLC by targeting FGF2 and CCND2, and may serve as a therapeutic target for patients with NSCLC. This evidence concerns the gene FGF2 and non-small cell lung carcinoma.